Geoffrey Greene to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Geoffrey Greene has written about Xenograft Model Antitumor Assays.
Connection Strength
0.524
-
PARP-1 as a novel target in endocrine-resistant breast cancer. J Exp Clin Cancer Res. 2025 Jun 16; 44(1):175.
Score: 0.203
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 06 07; 26(1):95.
Score: 0.189
-
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018 06 18; 9(1):2368.
Score: 0.031
-
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
Score: 0.031
-
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017 03; 7(3):277-287.
Score: 0.028
-
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
Score: 0.021
-
MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013 Jan; 137(2):373-82.
Score: 0.021